Table 2. Characteristics of the Patient Cohort for the Concordance Study.
| Characteristics | No. (%) | |
|---|---|---|
| Feasibility cohort (n = 1210) | Concordance cohort (n = 100) | |
| Age at stage IV diagnosis, median (IQR), y | 69.0 (62.0-76.0) | 67.5 (60.8-76.0) |
| Sex | ||
| Female | 591 (48.8) | 51 (51.0) |
| Male | 619 (51.2) | 49 (49.0) |
| Race | ||
| Asian | 31 (2.6) | 3 (3.0) |
| Black/African American | 42 (3.5) | 1 (1.0) |
| Unknowna | 155 (12.8) | 6 (6.0) |
| White | 886 (73.2) | 84 (84.0) |
| Otherb | 96 (7.9) | 6 (6.0) |
| Histologic findings | ||
| Nonsquamous cell | 919 (76.0) | 83 (83.0) |
| NOS | 49 (4.0) | 0 |
| Squamous cell | 242 (20.0) | 17 (17.0) |
| Smoking history | ||
| Yes | 992 (82.0) | 82 (82.0) |
| No | 215 (17.8) | 18 (18.0) |
| Unknown | 3 (0.2) | 0 |
| Stage IV diagnosis year | ||
| 2011-2014 | 497 (41.1) | 36 (36.0) |
| 2015-2017 | 501 (41.4) | 49 (49.0) |
| ≥2018 | 212 (17.5) | 15 (15.0) |
| EGFR variant | ||
| Tested | 585 (48.3) | 54 (54.0) |
| Variation negative | 433 (74.0) | 37 (68.5) |
| Variation positive | 114 (19.5) | 13 (24.1) |
| Other | 38 (6.5) | 4 (7.4) |
| ALK alteration | ||
| Tested | 580 (47.9) | 52 (52.0) |
| Rearrangement not present | 496 (85.5) | 48 (92.3) |
| Rearrangement present | 25 (4.3) | 3 (5.8) |
| Other | 59 (10.2) | 1 (1.9) |
| KRAS variant | ||
| Tested | 195 (16.1) | 17 (17.0) |
| Variation negative | 121 (62.1) | 7 (41.2) |
| Variation positive | 62 (31.8) | 9 (52.9) |
| Other | 12 (6.2) | 1 (5.9) |
| 1L therapy | ||
| ALK inhibitor | 22 (1.8) | 3 (3.0) |
| Anti–VEGF-containing | 192 (15.9) | 27 (27.0) |
| Clinical study | 6 (0.5) | 0 |
| EGFR TKI | 128 (10.6) | 19 (19.0) |
| Anti-EGFR antibody-based | 3 (0.2) | 1 (1.0) |
| Nonplatinum-based chemoth comb | 3 (0.2) | 0 |
| Other | 1 (0.1) | 0 |
| PD-(L)1-based | 182 (15.1) | 15 (15.0) |
| Platinum-based chemoth comb | 631 (52.4) | 35 (35.0) |
| Single-agent chemotherapy | 37 (3.1) | 0 |
Abbreviations: ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; IQR, interquartile range; NOS, not otherwise specified; PD-(L)1, programmed cell death-(ligand) 1; TKI, tyrosine kinase inhibitor; VEGF, vascular endothelial growth factor.
a
Patients whose race was either not captured or who only had “Hispanic or Latino” ethnicity captured without race, were categorized as “Unknown” owing to small cohort size.
b
Patients with race category not listed above were categorized as "Other."